



Prpdp-LevETIRAcetam Oral Solution 100 mg/mL Now Available

PENDOPHARM is proud to announce the launch of Prpdp-LevETIRAcetam Oral Solution 100 mg/mL effective immediately.



Prpdp-LevETIRAcetam (levetiracetam) is the first oral solution of this antiepileptic agent with a Health Canada approved indication for the pediatric population. Prpdp-LevETIRAcetam Oral Solution is indicated as adjunctive therapy¹ in the treatment of:

- **Partial onset seizures with or without secondary generalization** in adolescents, children and infants, from **one month of age**, who have epilepsy;
- **Myoclonic seizures**, in adolescents, from the age of 12 years, who have juvenile myoclonic epilepsy;
- **Primary generalized tonic-clonic seizures**, in adolescents, from the age of 12 years, who have generalized idiopathic epilepsy.

UPC Code	DIN	Product Description	Format
625972013782	02490447	Prpdp-LevETIRAcetam Oral Solution 100 mg/mL	300 mL

For important information relating to contraindications, warnings, precautions, adverse reactions, drug interactions, dosing and conditions of clinical use please refer to product monograph at https://pdf.hres.ca/dpd_pm/00052139.PDF or also available by calling 1-888-550-6060.

To place an order for the **Oral Solution of Prpdp-LevETIRAcetam 100 mg/mL**, please contact your distributor. For any inquiries, please contact PENDOPHARM Customer Service department at 1-866-926-7653.

1. For patients who are not satisfactorily controlled by conventional therapy.